Cleared Traditional

K780671 - 125 I-T3 UPTAKE REAGENT

K780671 is the FDA 510(k) clearance for 125 I-T3 UPTAKE REAGENT by Radioimmunoassay, Inc.. It is a Class 2 Chemistry device (product code CEE) cleared through the Traditional 510(k) pathway after a 43-day FDA review.

K780671 · Radioimmunoassay, Inc. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1978
Decision
43d
Days
Class 2
Risk

K780671 is an FDA 510(k) clearance for the 125 I-T3 UPTAKE REAGENT. Classified as Radioimmunoassay, Thyroxine-binding Globulin (product code CEE), Class II - Special Controls.

Submitted by Radioimmunoassay, Inc. (Mchenry, US). The FDA issued a Cleared decision on June 6, 1978 after a review of 43 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1685 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Radioimmunoassay, Inc. devices

Submission Details

510(k) Number K780671 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 24, 1978
Decision Date June 06, 1978
Days to Decision 43 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
45d faster than avg
Panel avg: 88d · This submission: 43d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code CEE Radioimmunoassay, Thyroxine-binding Globulin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1685
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - CEE Radioimmunoassay, Thyroxine-binding Globulin

All 18
Devices cleared under the same product code (CEE) and FDA review panel - the closest regulatory comparables to K780671.
TBG DIAGNOSTIC KIT
K820252 · Diagnostic Reagents, Inc. · May 1982
RIA PHASE TBG
K800204 · Boehringer Mannheim Corp. · Mar 1980
GLOBULIN TEST, HUMAN THYROXINE BINDING
K781225 · Hyland Therapeutic Div., Travenol Laboratories · Aug 1978
THYROID BINDING GLOBULIN
K772183 · Corning Medical & Scientific · Dec 1977
PROCEDURE, RA, THYROXINE BINDING PROTEIN
K760134 · Bio-Rad · Jul 1976